Ginkgo Bioworks reported its financial results for the first quarter ended March 31, 2025, on May 6, 2025, with total revenue reaching $48.318 million, a 27% increase from $37.944 million in Q1 2024. Cell Engineering revenue grew 37% year-over-year to $38.230 million.
The company's net loss improved to $(90.957) million in Q1 2025, compared to a net loss of $(165.911) million in Q1 2024. Net cash used in operating activities for the quarter was $(51.521) million.
Ginkgo reaffirmed its full-year 2025 total revenue guidance of $167 million to $187 million. The company also noted continued progress towards its expanded $250 million cost savings target, highlighting a solid base from significant restructuring efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.